Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20585605 | 0.86 | CHRM1 (0.51) | MEN1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL20585603 | 0.86 | CHRM1 (0.51) | MEN1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL20585602 | 0.86 | CHRM1 (0.51) | MEN1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL29638838 | 0.84 | NR1H2 (0.47) | HPGDGPR119RECQLEPHX1MEN1 | |
| SCHEMBL21349508 | 0.84 | NR1H2 (0.47) | HPGDGPR119RECQLEPHX1MEN1 | |
| SCHEMBL20585864 | 0.82 | NR1H2 (0.34) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL20585866 | 0.82 | NR1H2 (0.34) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL20585868 | 0.82 | NR1H2 (0.34) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL20585708 | 0.82 | CHRM1 (0.47) | MEN1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL20585711 | 0.82 | CHRM1 (0.47) | MEN1ALDH1A1KMT2ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10329278-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329278-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HPGD 2253/4885GPR119 102/4885RECQL 787/4885 |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | HPGD 2119/4885GPR119 107/4885RECQL 822/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HPGD 2119/4885GPR119 107/4885RECQL 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.